Altamont Capital Partners (Altamont) invested in the pharmaceutical commercialization market when it acquired Publicis Group’s’ outsourced sales rep and call center businesses (PHS Health Solutions) in January 2019.
At the time acquisition, Altamont indicated that it would grow the business by adding capabilities in medical communications, data-based analytical insights and pricing and market access.
In May 2019, PHS announced the company would operate under the new identity of Amplity Health. Amplity Health (Amplity) provides customized, live channel healthcare sales, service and clinical solutions for pharmaceutical, biotechnology, medical device and diagnostics companies and offers these services through a range of brands including Publicis Touchpoint Solutions, PDI, Tardis Medical, Phrequency and CustomPoint Recruiting.
In January 2020, Amplity acquired RealHealthData, a pharmaceutical data services provider specializing in providing patient and provider insights. RealHealthData is being integrated into the Amplity service offerings as Amplity Insights.
Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, recently agreed with Amplity Health to provide community-based commercial and sales services for SIVEXTRO and XENLETA® in the U.S.
SIVEXTRO is an oxazolidinone-class antibacterial indicated in adults and pediatric patients 12 years of age and older for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible Gram-positive microorganisms.
Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
Takeaway: With Altamont’s support, Amplity will be able to make investments to improve and expand its capabilities